title: [The use of antithyroid drugs should be reduced as much as possible in the first trimester].
abstract: The treatment of choice for hyperthyroidism in pregnancy is antithyroid drugs, but the potential risk of birth defects is of major concern. For the use of thiamazole and carbimazole, there is consistent evidence of an increased risk of birth defects, which are often severe. For the use of propylthiouracil, the evidence is less clear. These birth defects may be less severe, and a Danish study which included all birth defects diagnosed before the age of two years showed an increased risk of birth defects in the face and neck region and in the urinary system after the use of propylthouracil.
authors.affiliation: Endokrinologisk Afdeling, Aalborg Universitetshospital, Sdr. Skovvej 15, 9000 Aalborg. E-mail: stine.a@rn.dk.
authors.forename: Stine Linding
authors.initials: SL
authors.lastname: Andersen
authors.forename: Peter
authors.initials: P
authors.lastname: Laurberg
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control; D013956:Antithyroid Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002231:Carbimazole / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy; D007231:Infant, Newborn; D008713:Methimazole / Q000008:administration & dosage / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011261:Pregnancy Trimester, First; D011441:Propylthiouracil / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors
chemical_list: D013956:Antithyroid Agents; D008713:Methimazole; D011441:Propylthiouracil; D002231:Carbimazole